Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.

Bhatwadekar AD, Kansara VS, Ciulla TA.

Expert Opin Investig Drugs. 2020 Jan 31:1-8. doi: 10.1080/13543784.2020.1723078. [Epub ahead of print]

PMID:
31985300
2.

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review.

Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM.

BMJ Open Ophthalmol. 2019 Dec 15;4(1):e000398. doi: 10.1136/bmjophth-2019-000398. eCollection 2019. Review.

3.

Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.

Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA.

Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. doi: 10.1080/13543784.2019.1667333. Epub 2019 Sep 26. Review.

PMID:
31513439
4.

Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies.

Buessing M, O'Connell T, Johnson S, Pitluck S, Ciulla TA.

Value Health. 2019 Aug;22(8):970-971. doi: 10.1016/j.jval.2018.12.013. Epub 2019 May 25. No abstract available.

PMID:
31426938
5.

Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.

Ciulla TA, Hussain RM, Pollack JS, Williams DF.

Ophthalmol Retina. 2020 Jan;4(1):19-30. doi: 10.1016/j.oret.2019.05.017. Epub 2019 May 25.

PMID:
31324588
6.

Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.

Johnson S, Buessing M, O'Connell T, Pitluck S, Ciulla TA.

JAMA Ophthalmol. 2019 Jul 18. doi: 10.1001/jamaophthalmol.2019.2512. [Epub ahead of print]

7.

Innovative therapies for neovascular age-related macular degeneration.

Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU.

Expert Opin Pharmacother. 2019 Oct;20(15):1879-1891. doi: 10.1080/14656566.2019.1636031. Epub 2019 Jul 12. Review.

PMID:
31298960
8.

Vascular dysfunction in retinitis pigmentosa.

Lang M, Harris A, Ciulla TA, Siesky B, Patel P, Belamkar A, Mathew S, Verticchio Vercellin AC.

Acta Ophthalmol. 2019 Nov;97(7):660-664. doi: 10.1111/aos.14138. Epub 2019 May 17. Review.

PMID:
31099494
9.

Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States.

Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC.

Ophthalmol Retina. 2018 Jul;2(7):645-653. doi: 10.1016/j.oret.2018.01.006. Epub 2018 Mar 1.

PMID:
31047372
10.

Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States.

Ciulla TA, Bracha P, Pollack J, Williams DF.

Ophthalmol Retina. 2018 Dec;2(12):1179-1187. doi: 10.1016/j.oret.2018.06.004. Epub 2018 Jul 29.

PMID:
31047187
11.

Complement inhibition as a therapeutic strategy in retinal disorders.

Kassa E, Ciulla TA, Hussain RM, Dugel PU.

Expert Opin Biol Ther. 2019 Apr;19(4):335-342. doi: 10.1080/14712598.2019.1575358. Epub 2019 Feb 11.

PMID:
30686077
12.

Vital Dyes in Vitreomacular Surgery.

Bracha P, Ciulla TA, Baumal CR.

Ophthalmic Surg Lasers Imaging Retina. 2018 Oct 1;49(10):788-798. doi: 10.3928/23258160-20181002-07. Review.

PMID:
30395665
13.

Stargardt macular dystrophy and evolving therapies.

Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW Jr, Lam BL.

Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059. doi: 10.1080/14712598.2018.1513486. Epub 2018 Sep 10. Review.

PMID:
30129371
14.

Pharmacotherapy of retinal disease with visual cycle modulators.

Hussain RM, Gregori NZ, Ciulla TA, Lam BL.

Expert Opin Pharmacother. 2018 Apr;19(5):471-481. doi: 10.1080/14656566.2018.1448060. Epub 2018 Mar 15. Review.

PMID:
29542350
15.

Gene therapy for inherited retinal and optic nerve degenerations.

Moore NA, Morral N, Ciulla TA, Bracha P.

Expert Opin Biol Ther. 2018 Jan;18(1):37-49. doi: 10.1080/14712598.2018.1389886. Epub 2017 Oct 23. Review.

PMID:
29057663
16.

Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency.

Hussain RM, Hariprasad SM, Ciulla TA.

Ophthalmic Surg Lasers Imaging Retina. 2017 Oct 1;48(10):780-784. doi: 10.3928/23258160-20170928-01. Review. No abstract available.

PMID:
29020420
17.

The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review.

Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB.

Surv Ophthalmol. 2018 May - Jun;63(3):281-295. doi: 10.1016/j.survophthal.2017.08.008. Epub 2017 Sep 5. Review.

PMID:
28882597
18.

Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration.

Hussain RM, Ciulla TA.

Expert Opin Emerg Drugs. 2017 Sep;22(3):235-246. doi: 10.1080/14728214.2017.1362390. Epub 2017 Aug 4. Review.

PMID:
28756707
19.

Gene therapy for age-related macular degeneration.

Moore NA, Bracha P, Hussain RM, Morral N, Ciulla TA.

Expert Opin Biol Ther. 2017 Oct;17(10):1235-1244. doi: 10.1080/14712598.2017.1356817. Epub 2017 Jul 20. Review.

PMID:
28726562
20.

LEAN SIX SIGMA TECHNIQUES TO IMPROVE OPHTHALMOLOGY CLINIC EFFICIENCY.

Ciulla TA, Tatikonda MV, ElMaraghi YA, Hussain RM, Hill AL, Clary JM, Hattab E.

Retina. 2018 Sep;38(9):1688-1698. doi: 10.1097/IAE.0000000000001761.

PMID:
28723845
21.

Induced pluripotent stem cell-based therapy for age-related macular degeneration.

Bracha P, Moore NA, Ciulla TA.

Expert Opin Biol Ther. 2017 Sep;17(9):1113-1126. doi: 10.1080/14712598.2017.1346079. Epub 2017 Jun 30. Review.

22.

Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.

Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Monés J, Pearlman JA, Quaranta-El Maftouhi M, Ricci F, Westby K, Patel SC.

Ophthalmology. 2017 Feb;124(2):224-234. doi: 10.1016/j.ophtha.2016.10.010. Epub 2016 Oct 28.

PMID:
28029445
23.

EFFICACY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR REFRACTORY MACULAR EDEMA CAUSED BY RETINAL VEIN OCCLUSION.

Hussain RM, Ciulla TA, Ciulla LM, Sink B, Harris A.

Retin Cases Brief Rep. 2018 Fall;12(4):294-299. doi: 10.1097/ICB.0000000000000496.

PMID:
27984545
24.

Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.

Hussain RM, Ciulla TA.

Expert Opin Biol Ther. 2016;16(3):365-74. doi: 10.1517/14712598.2016.1131265. Epub 2016 Jan 12. Review.

25.

RANIBIZUMAB FOR DIABETIC MACULAR EDEMA REFRACTORY TO MULTIPLE PRIOR TREATMENTS.

Ciulla TA, Hussain RM, Ciulla LM, Sink B, Harris A.

Retina. 2016 Jul;36(7):1292-7. doi: 10.1097/IAE.0000000000000876.

26.

Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Ciulla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, Daniel E, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2015 Jun;122(6):1203-11. doi: 10.1016/j.ophtha.2015.02.031. Epub 2015 Mar 29. Erratum in: Ophthalmology. 2015 Aug;122(8):1733. Cuilla, Thomas A [Corrected to Ciulla, Thomas A].

27.

Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.

Ciulla TA, Harris A, McIntyre N, Jonescu-Cuypers C.

Expert Opin Pharmacother. 2014 May;15(7):953-9. doi: 10.1517/14656566.2014.896899. Epub 2014 Mar 24. Review.

PMID:
24661081
28.

Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.

Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM; Ozurdex PLACID Study Group.

Ophthalmology. 2013 Sep;120(9):1843-51. doi: 10.1016/j.ophtha.2013.02.018. Epub 2013 May 22.

PMID:
23706947
29.

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study.

Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Campochiaro PA; READ-2 Study Group.

Ophthalmology. 2010 Nov;117(11):2146-51. doi: 10.1016/j.ophtha.2010.08.016. Epub 2010 Sep 19. Erratum in: Ophthalmology. 2011 Jun;118(6):1016. Eliot, Dean [corrected to Eliott, Dean].

PMID:
20855114
30.

Response to: Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion by Schroff et al..

Ehrlich R, Ciulla TA, Moss A, Harris A.

Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):305. doi: 10.1007/s00417-010-1354-5. Epub 2010 Mar 30. No abstract available.

PMID:
20352444
31.

Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process.

Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B.

Acta Ophthalmol. 2010 May;88(3):279-91. doi: 10.1111/j.1755-3768.2008.01501.x. Epub 2010 Mar 11. Review.

32.

Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up.

Ehrlich R, Ciulla TA, Moss AM, Harris A.

Graefes Arch Clin Exp Ophthalmol. 2010 Mar;248(3):375-80. doi: 10.1007/s00417-009-1211-6. Epub 2009 Nov 8.

PMID:
19898827
33.

Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.

Ehrlich R, Ciulla TA, Maturi R, Kheradiya NS, Hrisomalos N, Shulman S, Guess MG, Coyle E, Harris A.

Retina. 2009 Nov-Dec;29(10):1418-23. doi: 10.1097/IAE.0b013e3181babdf1.

PMID:
19898179
34.

Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.

Ciulla TA, Rosenfeld PJ.

Curr Opin Ophthalmol. 2009 May;20(3):158-65. doi: 10.1097/ICU.0b013e32832d25b3. Review.

PMID:
19417570
35.

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.

Ciulla TA, Rosenfeld PJ.

Curr Opin Ophthalmol. 2009 May;20(3):166-74. doi: 10.1097/ICU.0b013e328329d173. Review.

PMID:
19381089
36.

Age-related macular degeneration and the aging eye.

Ehrlich R, Harris A, Kheradiya NS, Winston DM, Ciulla TA, Wirostko B.

Clin Interv Aging. 2008;3(3):473-82. Review.

37.

Pharmacologic therapies for diabetic retinopathy and diabetic macular edema.

Rechtman E, Harris A, Garzozi HJ, Ciulla TA.

Clin Ophthalmol. 2007 Dec;1(4):383-91.

38.

How the diabetic eye loses vision.

Davidson JA, Ciulla TA, McGill JB, Kles KA, Anderson PW.

Endocrine. 2007 Aug;32(1):107-16. Epub 2007 Sep 27. Review.

PMID:
17992608
39.

The relationship between retrobulbar and choroidal hemodynamics in non-neovascular age-related macular degeneration.

Rechtman E, Harris A, Siesky B, Kagemann L, Danis RP, Sines D, Ciulla TA.

Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):219-25. doi: 10.3928/15428877-20070501-06.

PMID:
17552388
40.

Sustained response to multiple intravitreal triamcinolone acetonide injections in a patient with predominantly occult choroidal neovascularization.

Oliver A, Ciulla TA.

Retin Cases Brief Rep. 2007 Winter;1(1):12-3. doi: 10.1097/01.ICB.0000256935.49060.d6. No abstract available.

PMID:
25390223
41.

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY; FOCUS Study Group.

Arch Ophthalmol. 2006 Nov;124(11):1532-42. Erratum in: Arch Ophthalmol. 2007 Jan;125(1):138.

PMID:
17101999
42.

Corticosteroids as antiangiogenic agents.

Oliver A, Ciulla TA.

Ophthalmol Clin North Am. 2006 Sep;19(3):345-51, v. Review.

PMID:
16935209
43.

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N.

Ophthalmology. 2006 Apr;113(4):633.e1-4. Epub 2006 Feb 14.

PMID:
16483659
44.

Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model.

Hu W, Criswell MH, Ottlecz A, Cornell TL, Danis RP, Lambrou GN, Ciulla TA.

Retina. 2005 Dec;25(8):1054-64.

PMID:
16340537
45.

Human vitreous distribution of linezolid after a single oral dose.

Ciulla TA, Comer GM, Peloquin C, Wheeler J.

Retina. 2005 Jul-Aug;25(5):619-24.

PMID:
16077360
46.

Current and future pharmacological intervention for diabetic retinopathy.

Comer GM, Ciulla TA.

Expert Opin Emerg Drugs. 2005 May;10(2):441-55. Review.

PMID:
15934878
47.

Anastomotic vessels remain viable after photodynamic therapy in primate models of choroidal neovascularization.

Criswell MH, Ciulla TA, Lowseth LA, Small W, Danis RP, Carson DL.

Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2168-74.

PMID:
15914638
48.

New and classic insights into presumed ocular histoplasmosis syndrome and its treatment.

Oliver A, Ciulla TA, Comer GM.

Curr Opin Ophthalmol. 2005 Jun;16(3):160-5. Review.

PMID:
15870572
49.

Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration.

Comer GM, Ciulla TA, Heier JS, Criswell MH.

Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35. Review.

PMID:
15757408
50.

Current and future treatment options for nonexudative and exudative age-related macular degeneration.

Comer GM, Ciulla TA, Criswell MH, Tolentino M.

Drugs Aging. 2004;21(15):967-92. Review.

PMID:
15631528

Supplemental Content

Loading ...
Support Center